Citi lowered the firm’s price target on Bristol Myers (BMY) to $45 from $48 and keeps a Neutral rating on the shares after the company announced the discontinuation of the Librexia acute coronary syndrome trial. Citi sees higher risk to the broader program following the news.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol-Myers Squibb Faces Setbacks with Milvexian Trials, Justifying Sell Rating
- Bristol Myers Squibb put volume heavy and directionally bearish
- Bristol Myers falls 4% to $46.41 after stopping Phase 3 Librexia ACS trial
- Bristol Myers to stop Phase 3 Librexia ACS trial of milvexian
- Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls